Anticoagulants Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 24.20 Billion |
| Market Size (2029) | USD 34.40 Billion |
| CAGR (2024 - 2029) | 7.29 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Anticoagulants Market Analysis
The Anticoagulants Market size is estimated at USD 24.20 billion in 2024, and is expected to reach USD 34.40 billion by 2029, growing at a CAGR of 7.29% during the forecast period (2024-2029).
Factors such as an increase in the incidence of chronic diseases with a rise in the adoption of novel anticoagulant medicines are likely to drive market growth. For example, according to the May 2024 update by the Centers for Disease Control and Prevention, about 1 in 20 adults aged 20 and older have coronary artery disease (CAD) in the United States. Further, as per the same source, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in the United States have a heart attack every year. Thus, the growing burden of coronary artery disease is expected to increase the demand for anticoagulants, thereby contributing to the growth of the market.
Moreover, the regulatory approval of anticoagulant products is also propelling the growth of the market. For example, in March 2023, Techdow USA Inc. received US Food and Drug Administration (FDA) approval for enoxaparin sodium (preservative-free) in prefilled syringes for the US market. The launch of Enoxaparin is expected to complement Techdow USA’s existing heparin sodium injection business, which was launched in 2022. Hence, the active presence of key market players and strategic product launches are expected to augment the market growth during the forecast period. Additionally, the demand for anticoagulants in chronic disease therapy is expected to drive market expansion during the forecast period. For instance, as per the BHF report published in 2023, 1,372 anticoagulant and protamine medicines were prescribed during 2021-2022 in Wales for the prevention and treatment of heart and circulatory diseases.
Therefore, the market is expected to witness notable growth during the forecast period due to the increase in chronic disease complications and advancements in anticoagulant therapies coupled with strategic activities by the key players. However, stringent regulation and side effects associated with the treatment will restrain the market growth during the forecast period.
Anticoagulants Market Trends
The Novel Oral Anticoagulants (NOACs) Segment is Expected to Hold Significant Market Share in the Anticoagulants Market During the Forecast Period
The novel oral anticoagulants (NOACs) segment is expected to hold a significant market share in the anticoagulants market and is anticipated to show a similar trend during the forecast period owing to the growing adoption of the novel oral anticoagulants (NOACs) in developing countries and the high preference of NOACs over the warfarin.
Novel oral anticoagulants (NOACs) are a new class of anticoagulant drugs. Moreover, these are safe (lower incidence of major bleeding), convenient to use, have no interactions with food, and have a shorter half-life. Some of the NOACs include dabigatran, rivaroxaban, apixaban, and edoxaban. These can be used to prevent and treat atrial fibrillation/myocardial infarction, deep vein thrombosis (DVT), and pulmonary embolism.
According to the Centers for Disease Control and Prevention (CDC) update in May 2024, each year in the United States, approximately 900,000 people ((1 to 2 per 1,000 population) could be affected by deep vein thrombosis. Also, according to the British Heart Foundation (BHF) January 2024 report, 7.6 million people in the United Kingdom live with heart and circulatory disease as of 2024. Thus, the increasing incidences of cardiovascular disorders, venous thromboembolism (VTE), and advancements in the development of novel products are the key driving factors in the novel oral anticoagulants (NOACs) segment.
During the forecast period, market growth is expected due to anticipated product launches and approvals. For instance, in June 2024, India's Central Drug Standard Control Organization approved Zuventus Healthcare's production and distribution of edoxaban, a new oral anticoagulant. However, the approval is contingent upon the company conducting a Phase IV clinical trial to further assess the drug's safety and efficacy. Similarly, in June 2022, Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, launched APO-Apixaban tablets, Canada's first generic alternative to Eliquis. Hence, owing to the significant product approvals and further marketing of NOACs, it is expected to drive the segment growth during the forecast period.
Hence, due to the increase in cardiovascular disease and strategic product launches by the key players, the segment is estimated to hold a significant market share during the forecast period.
North America is Anticipated to Hold a Significant Market Share During the Forecast Period
North America is expected to hold a significant market share in the anticoagulants market due to the high demand for innovative products and the increasing prevalence of cardiovascular disorders in this region. For instance, according to the July 2022 Canadian Institute for Health Information (CIHI) update, about 2.4 million Canadians lived with heart disease in 2022. Also, as per the Heart Failure Report 2022, more than 100,000 Canadians are diagnosed with heart failure each year. Thus, with the increase in cardiovascular diseases, the demand for anticoagulants increases in the region, thereby boosting the market.
Also, the presence of top pharma and biotech companies involved in the development of therapeutics and the presence of well-established healthcare infrastructure are fueling the growth of the overall regional market to a large extent. For instance, in November 2023, Pharmascience Canada introduced pms-RIVAROXABAN, a generic drug entirely produced in Canada. This drug is classified as an anticoagulant, commonly known as a blood thinner. By directly inhibiting the activity of Factor-Xa, a key clotting factor, it effectively prevents the formation of blood clots pms-RIVAROXABAN comes in oral tablet forms of 2.5 mg, 10 mg, 15 mg, and 20 mg. For instance, in February 2022, CD Bioparticles, a manufacturer and provider of diverse drug delivery goods and services, launched several heparin products, including heparin biotin, heparin amine, and heparin thiol, and made available to support drug delivery research.
Therefore, due to the increase in cardiovascular disease and strategic activities by the key players, North America is estimated to hold a sizable proportion of the market during the forecast period.
Anticoagulants Industry Overview
The anticoagulants market is semi-consolidated and consists of several major players. Some of the major players operating in the market include Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, GlaxoSmithKline PLC, Aspen Holdings, Sanofi, Pfizer Inc., and Portola Pharmaceuticals Inc.
Anticoagulants Market Leaders
-
Johnson & Johnson
-
Bayer AG
-
Boehringer Ingelheim GmbH
-
Bristol-Myers Squibb Company
-
Daiichi Sankyo Company
*Disclaimer: Major Players sorted in no particular order
Anticoagulants Market News
- August 2024: Alembic Pharmaceuticals secured final approval from the US Food and Drug Administration for its 110 mg dabigatran etexilate capsules. This is a generic version of Boehringer Ingelheim's 110 mg PRADAXA capsules. These capsules help mitigate the risk of pulmonary embolism and deep vein thrombosis following hip replacement surgery.
- July 2024: Adalvo secured decentralized procedure (DCP) approval for its apixaban tablets. Apixaban, referencing the brand Eliquis, is prescribed for treating deep vein thrombosis (DVT) and pulmonary embolism (PE).
Anticoagulants Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Cases of Chronic Diseases
4.2.2 Increase in Development of Anticoagulant Products and Growing Adoption of Novel Oral Anticoagulants (NOACs)
4.3 Market Restraints
4.3.1 Stringent Government Regulations
4.3.2 Side Effects Associated with Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Drug Class
5.1.1 Novel Oral Anticoagulants (NOACs)
5.1.2 Heparin and Low Molecular Weight Heparin (LMWH)
5.1.3 Vitamin K Antagonist
5.2 By Application
5.2.1 Atrial Fibrillation/Myocardial Infarction
5.2.2 Deep Vein Thrombosis (DVT)
5.2.3 Pulmonary Embolism
5.2.4 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Johnson & Johnson
6.1.2 Bayer AG
6.1.3 Boehringer Ingelheim GmbH
6.1.4 Bristol-Myers Squibb Company
6.1.5 Daiichi Sankyo Company
6.1.6 Abbott
6.1.7 Aspen Holdings
6.1.8 Sanofi
6.1.9 Pfizer Inc.
6.1.10 Alexion Pharmaceuticals Inc.
6.1.11 Leo Pharma AS
6.1.12 Dr. Reddy’s Laboratories
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Anticoagulants Industry Segmentation
As per the scope of the report, anticoagulants are medicines used to treat and prevent blood clots that may occur in blood vessels.
The anticoagulants market is segmented by drug class, application, and geography. By drug class, the market is segmented into novel oral anticoagulants (NOACs), heparin, low molecular weight heparin (LMWH), and vitamin K antagonists. By application, the market is segmented into atrial fibrillation/myocardial infarction, deep vein thrombosis (DVT), pulmonary embolism, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for the above segments.
| By Drug Class | |
| Novel Oral Anticoagulants (NOACs) | |
| Heparin and Low Molecular Weight Heparin (LMWH) | |
| Vitamin K Antagonist |
| By Application | |
| Atrial Fibrillation/Myocardial Infarction | |
| Deep Vein Thrombosis (DVT) | |
| Pulmonary Embolism | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Anticoagulants Market Research Faqs
How big is the Anticoagulants Market?
The Anticoagulants Market size is expected to reach USD 24.20 billion in 2024 and grow at a CAGR of 7.29% to reach USD 34.40 billion by 2029.
What is the current Anticoagulants Market size?
In 2024, the Anticoagulants Market size is expected to reach USD 24.20 billion.
Who are the key players in Anticoagulants Market?
Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company and Daiichi Sankyo Company are the major companies operating in the Anticoagulants Market.
Which is the fastest growing region in Anticoagulants Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Anticoagulants Market?
In 2024, the North America accounts for the largest market share in Anticoagulants Market.
What years does this Anticoagulants Market cover, and what was the market size in 2023?
In 2023, the Anticoagulants Market size was estimated at USD 22.44 billion. The report covers the Anticoagulants Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Anticoagulants Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Anticoagulants Industry Report
The report covers the global oral anticoagulant market and is segmented by drug class, which includes novel oral anticoagulants (NOACs), heparin and low molecular weight heparin (LMWH), and vitamin K antagonist. Applications are divided into atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis (DVT), pulmonary embolism, and other applications, with geography segments including North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market size and forecasts are provided in terms of value for these segments.
This comprehensive industry analysis provides valuable industry information and highlights key industry trends. The market report offers a detailed market overview and market segmentation, giving insights into market leaders and market growth. The report includes a market forecast and market outlook, presenting an industry outlook that is crucial for understanding the market value and market data.
The report also includes industry research and industry statistics, which are essential for understanding the market size and industry size. The market analysis covers the market share and market shares, providing a clear picture of the market's performance. Additionally, the report discusses the growth rate and industry sales, offering a thorough market review and industry reports.
For those seeking detailed industry research, this report includes a report example and a report PDF for further reference. The research companies involved have ensured that the market predictions are accurate, providing a reliable source of market information for stakeholders.
